EMA Authorised: Hemgenix (Etranacogene dezaparvovec) — CSL Behring GmbH

View source ↗

Summary

The EMA has authorised Hemgenix (etranacogene dezaparvovec) for Hemophilia B under conditional approval as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia B

Drugs mentioned

• Hemgenix (etranacogene dezaparvovec)

Snippet

Status: Authorised. Therapeutic area: Hemophilia B. MAH: CSL Behring GmbH. Decision date: 21/05/2026. Conditional approval. Orphan medicine